166 related articles for article (PubMed ID: 36505870)
1. Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy.
Liu X; Zheng Y; Mai S; Tong Y; Yang L; Huang M; Cai R
Front Oncol; 2022; 12():1033322. PubMed ID: 36505870
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report.
Wang H; Wu Z; Du Y; Wu T; Tian W; Dong W; Cai J; Zheng J; Zhang Y; Li S; Xu W; Qin J; Xiao Z
Front Oncol; 2023; 13():1145021. PubMed ID: 36969031
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report.
Chen R; Zhao L; Zhang J; Guo L; Chen Z; Pan X; Chen W
Heliyon; 2023 Nov; 9(11):e21582. PubMed ID: 38034719
[TBL] [Abstract][Full Text] [Related]
4. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
6. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
8. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)
Xiong L; Li R; Sun J; Lou Y; Zhang W; Bai H; Wang H; Shen J; Jing B; Shi C; Zhong H; Gu A; Jiang L; Shi J; Fang W; Zhao H; Zhang J; Wang J; Ye J; Han B
Oncologist; 2019 Feb; 24(2):157-e64. PubMed ID: 30158288
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report.
Wang Y; Yang X; Tian X; Jia Z; Bing Z; Cao L; Gao C; Cao Z; Li S; Liang N
Ann Palliat Med; 2020 Nov; 9(6):4339-4345. PubMed ID: 33183013
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
13. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
Han ZJ; Luo N; Li L; Liu ZL
Ann Palliat Med; 2021 Jul; 10(7):8413-8419. PubMed ID: 33977727
[TBL] [Abstract][Full Text] [Related]
14. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
17. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
18. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
Zhang C; Sun YX; Yi DC; Jiang BY; Yan LX; Liu ZD; Peng LS; Zhang WJ; Sun H; Chen ZY; Wang DH; Peng D; Chen SA; Li SQ; Zhang Z; Tan XY; Yang J; Zhao ZY; Zhang WT; Su J; Li YS; Liao RQ; Dong S; Xu CR; Zhou Q; Yang XN; Wu YL; Zhang ZM; Zhong WZ
Cell Rep Med; 2024 Jun; ():101615. PubMed ID: 38897205
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series.
Hu Y; Ren S; Yang L; Tong Z; Wang R; Han W; Zeng C; Li J; Xiao P; Wang L; Yu F; Liu W
Front Pharmacol; 2022; 13():912153. PubMed ID: 35571073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
